CO4910132A1 - Agonistas adrenergicos selectivos de beta 3 - Google Patents

Agonistas adrenergicos selectivos de beta 3

Info

Publication number
CO4910132A1
CO4910132A1 CO97051043A CO97051043A CO4910132A1 CO 4910132 A1 CO4910132 A1 CO 4910132A1 CO 97051043 A CO97051043 A CO 97051043A CO 97051043 A CO97051043 A CO 97051043A CO 4910132 A1 CO4910132 A1 CO 4910132A1
Authority
CO
Colombia
Prior art keywords
alkyl
hydrogen
bond
beta
adrenergic agonists
Prior art date
Application number
CO97051043A
Other languages
English (en)
Inventor
Thomas Alan Crowell
Deborah Ann Evrard
Charles David Jones
Brian Stephen Muehl
Christopher John Rito
Anthony John Shuker
Andrew John Thorpe
Kenneth Jeff Thrasher
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4910132A1 publication Critical patent/CO4910132A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El uso de un compuesto de Fórmula I para estimular elreceptor ß3 :en la que:X1 es -OCH2 -, -SCH2 - o un enlace;X2 es un enlace, o un alquileno lineal o ramificado de 1 a 5 carbonos;X3 es O, S o un enlace;R1 es un heterociclo condensado de la fórmula:los grupos A1 son, independientemente, carbono o nitrógeno, con la condición de que no pueden estar incluidos más de 2 nitrógenos en ningún anillo condensado de 6 miembros, y de que esos 2 nitrógenos no pueden ser adyacentes;R2 es, independientemente, hidrógeno, alquilo C1 -C4 o arilo;R3 es, hidrógeno, alquilo C1 -C4 ;R4 es, un heterociclo opcionalmente sustituido, o un radical seleccionado entre el grupo compuesto por:R5 es hidrógeno o alquilo C1 -C4 ;R6 es hidrógeno o alquilo C1 -C4 ; oo R5 y R6 se combinan con el carbono al que está unido cada uno, ...
CO97051043A 1996-09-05 1997-09-03 Agonistas adrenergicos selectivos de beta 3 CO4910132A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2581896P 1996-09-05 1996-09-05
US2922896P 1996-10-30 1996-10-30

Publications (1)

Publication Number Publication Date
CO4910132A1 true CO4910132A1 (es) 2000-04-24

Family

ID=26700197

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97051043A CO4910132A1 (es) 1996-09-05 1997-09-03 Agonistas adrenergicos selectivos de beta 3

Country Status (13)

Country Link
US (4) US6140352A (es)
EP (1) EP0827746B1 (es)
JP (1) JP4212117B2 (es)
AR (2) AR009519A1 (es)
AT (1) ATE215369T1 (es)
AU (1) AU4094197A (es)
CO (1) CO4910132A1 (es)
DE (1) DE69711519T2 (es)
ES (1) ES2171839T3 (es)
ID (1) ID17182A (es)
MY (1) MY132626A (es)
PE (1) PE109398A1 (es)
WO (1) WO1998009625A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69711519T2 (de) * 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazolanaloge als selektive beta3-adrenergische Agonisten
US6232337B1 (en) * 1997-12-05 2001-05-15 Eli Lilly And Company Selective β3 adrenergic agonists
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
CN1333760A (zh) * 1998-12-15 2002-01-30 旭化成株式会社 新杂环化合物以及含此化合物的药用组合物
WO2001007026A2 (en) * 1999-07-22 2001-02-01 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
WO2001007025A2 (en) * 1999-07-22 2001-02-01 Eli Lilly And Company Treatment of cardiac abnormalities with aryloxy propanolamines
WO2001035947A2 (en) * 1999-11-15 2001-05-25 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines
US6841563B1 (en) * 1999-11-15 2005-01-11 Eli Lilly And Company Aryloxy propanolamines for improving livestock production
WO2001036412A1 (en) * 1999-11-15 2001-05-25 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
KR20020059730A (ko) * 1999-11-15 2002-07-13 피터 지. 스트링거 가축 생산성 개선을 위한 아릴옥시 프로판올아민
JP2003520226A (ja) 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
EP1258253A1 (en) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
AUPQ585000A0 (en) * 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
HUP0300894A3 (en) * 2000-03-15 2008-05-28 Sanofi Aventis Deutschland Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
DK1303509T3 (da) * 2000-07-13 2013-01-02 Lilly Co Eli Beta3 adrenerge agonister
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6537994B2 (en) * 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
DE60120748T2 (de) 2000-11-10 2007-05-16 Eli Lilly And Co., Indianapolis 3-substituierte oxindolderivate als beta-3-agonisten
KR100408122B1 (ko) * 2000-12-08 2003-12-01 한국디디에스제약 주식회사 광학 입체 이성질체의 성질을 갖는 베타 아드레날린 길항제의 제조 방법
DE60215028T2 (de) 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
ATE325119T1 (de) 2001-08-14 2006-06-15 Lilly Co Eli 3-substituierte oxindol-beta-3-agonisten
EP1448561B1 (en) 2001-11-20 2008-02-20 Eli Lilly And Company Beta 3 adrenergic agonists
WO2003044016A1 (en) 2001-11-20 2003-05-30 Eli Lilly And Company 3-SUBSTITUTED OXINDOLE β3 AGONISTS
JP2005520805A (ja) 2002-01-11 2005-07-14 イーライ・リリー・アンド・カンパニー ２−オキソ−ベンズイミダゾリル置換型エタノールアミン誘導体およびβ３アゴニストとしてのその使用
PT1562595E (pt) 2002-09-19 2008-07-28 Lilly Co Eli Éteres diarílicos como antagonistas de receptor de opióides
CN1756746A (zh) * 2003-03-07 2006-04-05 伊莱利利公司 作为阿片样物质受体拮抗剂的6－取代的烟酰胺衍生物
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
DE602004024668D1 (de) * 2003-04-23 2010-01-28 Japan Tobacco Inc CaSR-ANTAGONIST
US7375100B2 (en) 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
WO2005061442A1 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
AU2004312312A1 (en) * 2003-12-22 2005-07-21 Eli Lilly And Company Opioid receptor antagonists
US7875730B2 (en) 2004-02-23 2011-01-25 Cadila Healthcare Ltd. Process for manufacture of racemic Carvedilol
US7834187B2 (en) * 2004-07-22 2010-11-16 Eli Lilly And Company Crystalline variable hydrate of (S)-6-(4-(2-((3-9H-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20070060528A1 (en) 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
ZA200803226B (en) * 2005-10-13 2009-11-25 Orchid Res Lab Ltd Heterocyclic Compounds as Pstat3/IL-6 Inhibitors
WO2007077111A1 (en) * 2005-12-30 2007-07-12 F. Hoffmann-La Roche Ag Compounds and methods for carbazole synthesis
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
KR20090051778A (ko) 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
BR112012006069A8 (pt) * 2009-09-18 2017-10-10 Adolor Corp Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
WO2011075777A1 (en) 2009-12-21 2011-06-30 The University Of Queensland Neuronal stimulation
PT2531501E (pt) 2010-02-03 2014-02-17 Takeda Pharmaceutical Inibidores da cinase de regulação do sinal de apoptose 1
WO2012099862A2 (en) * 2011-01-20 2012-07-26 Videojet Technologies Inc. System for measuring ribbon tension
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
US20130317068A1 (en) * 2012-05-08 2013-11-28 Dow Agrosciences Llc Substituted 1,2,4-triazole compounds as a seed treatment to control pests
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
EP2903452A1 (en) 2012-10-02 2015-08-12 Eli Lilly and Company Methods for improving chicken production
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
US20190119642A1 (en) 2016-03-15 2019-04-25 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10865163B2 (en) 2017-12-20 2020-12-15 The University Of Toledo Carbon dioxide as a directing group for C—H functionalization reactions involving Lewis basic amines, alcohols, thiols, and phosphines for the synthesis of compounds
CN110668994A (zh) * 2019-11-12 2020-01-10 山东创新药物研发有限公司 左旋卡维地洛盐晶型、其制备方法及应用
CN115611752A (zh) * 2022-10-21 2023-01-17 江苏天和制药有限公司 一种卢巴贝隆中间体的合成精制方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2516E (fr) 1903-08-17 1904-04-27 Joseph Henri Desgeorge Perfectionnement aux appareils photographiques
SE379196B (es) * 1971-06-24 1975-09-29 Sandoz Ag
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPS5310974B2 (es) * 1974-06-10 1978-04-18
CH624395A5 (es) * 1976-01-08 1981-07-31 Ciba Geigy Ag
DE2609645A1 (de) * 1976-03-09 1977-09-15 Boehringer Sohn Ingelheim Aminoalkylheterocyclen
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
US4235919A (en) * 1977-07-21 1980-11-25 Sandoz Ltd. 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof
DE2830211A1 (de) * 1977-07-21 1979-02-01 Sandoz Ag Substituierte indol-derivate, ihre herstellung und verwendung
CA1108619A (en) * 1977-08-12 1981-09-08 Carl H. Ross 4-hydroxy-2-benzimidazolinone derivatives and the preparation thereof
DE2805404A1 (de) * 1978-02-09 1979-08-16 Merck Patent Gmbh 1-aryloxy-3-nitratoalkylamino-2-propanole und verfahren zu ihrer herstellung
EP0006735B1 (en) * 1978-06-28 1983-06-15 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
US4391826A (en) * 1978-07-03 1983-07-05 Eli Lilly And Company Phenethanolamines, compositions containing the same, and method for effecting weight control
CH636856A5 (en) * 1978-07-17 1983-06-30 Sandoz Ag 4-(3-Aminopropoxy)indole derivatives, their preparation and medicines containing them
US4751246A (en) * 1978-08-30 1988-06-14 Sterling Drug Inc. Compositions and method
DE2905877A1 (de) * 1979-02-16 1980-08-28 Boehringer Mannheim Gmbh Neue aminopropanolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DD150456A5 (de) * 1979-03-01 1981-09-02 Ciba Geigy Ag Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
EP0023385B1 (en) * 1979-06-16 1982-12-15 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
ATE1899T1 (de) * 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
EP0025331B1 (en) * 1979-09-06 1983-03-02 Beecham Group Plc Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them
DE3161165D1 (en) * 1980-05-08 1983-11-17 Beecham Group Plc Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions
DE3162756D1 (en) * 1980-05-22 1984-04-26 Beecham Group Plc Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions
CA1175851A (en) * 1980-09-26 1984-10-09 Beecham Group Limited Secondary amines
DE3169094D1 (en) * 1980-11-20 1985-03-28 Beecham Group Plc Secondary amines
EP0066351B1 (en) * 1981-03-06 1985-06-26 Beecham Group Plc Arylethanol amine derivatives, their preparation and use in pharmaceutical compositions
EP0061907B1 (en) * 1981-03-31 1984-08-01 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
EP0063004A1 (en) * 1981-04-09 1982-10-20 Beecham Group Plc Secondary amines, processes for their preparation, and pharmaceutical compositions containing them
EP0068669A1 (en) * 1981-06-20 1983-01-05 Beecham Group Plc Secondary phenylethanol amines, processes for their preparation and their pharmaceutical application
EP0070134B1 (en) * 1981-07-11 1985-11-13 Beecham Group Plc Secondary phenyl ethanol amines and their pharmaceutical use
FR2516512A1 (fr) * 1981-11-19 1983-05-20 Corbiere Jerome Nouveaux derives pyridoindoliques, leur procede de preparation et les compositions pharmaceutiques en contenant
IE54220B1 (en) * 1981-12-23 1989-07-19 Ici Plc Phenol esters
EP0089154A3 (en) * 1982-03-12 1984-08-08 Beecham Group Plc Ethanolamine derivatives, their preparation and use in pharmaceutical compositions
FR2523965B1 (fr) * 1982-03-24 1985-09-27 Bellon Labor Sa Roger (benzimidazolyl-1)-1, n-((hydroxy-4 methoxy-3 phenyl)-2 hydroxy-2 ethyl) amino-3 butane et ses sels a activite b-adrenergique, leurs applications therapeutiques, et procede pour les preparer
DE3360426D1 (en) * 1982-04-08 1985-08-29 Beecham Group Plc N-substituted derivatives of ethanol amine
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
CA1219865A (en) * 1982-05-14 1987-03-31 Leo Alig Aziridine phenethanolamine derivatives
DE3368258D1 (en) * 1982-07-16 1987-01-22 Beecham Group Plc 2-aminoethyl ether derivatives, processes for their preparation and pharmaceutical compositions containing them
EP0102213A1 (en) * 1982-08-21 1984-03-07 Beecham Group Plc Ethanolamine derivatives, pharmaceutical compositions containing them, and processes for preparing them
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US5166218A (en) * 1983-10-19 1992-11-24 Hoffmann-La Roche Inc. Phenoxypropanolamines and pharmaceutical compositions thereof
CA1262729A (en) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
GB8419797D0 (en) * 1984-08-03 1984-09-05 Beecham Group Plc Compounds
GB8507942D0 (en) * 1985-03-27 1985-05-01 Beecham Group Plc Compounds
IL79323A (en) * 1985-07-10 1990-03-19 Sanofi Sa Phenylethanolaminotetralines,their preparation and pharmaceutical compositions containing them
GB8519154D0 (en) * 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
EP0300290B1 (de) * 1987-07-21 1991-12-18 F. Hoffmann-La Roche Ag Phenoxypropanolamine
DE3800096A1 (de) * 1988-01-05 1989-07-13 Bayer Ag Verwendung von benzimidazolderivaten als leistungsfoerderer
GB8801306D0 (en) * 1988-01-21 1988-02-17 Ici Plc Chemical compounds
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
ATE117980T1 (de) * 1988-06-03 1995-02-15 Lilly Co Eli Serotonin-antagonisten.
IT1226726B (it) * 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
GB8905336D0 (en) * 1989-03-08 1989-04-19 Ici Plc Chemical compounds
DE4040186A1 (de) * 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
IE65511B1 (en) * 1989-12-29 1995-11-01 Sanofi Sa New phenylethanolaminomethyltetralins
US5360811A (en) * 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
US5061727A (en) * 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
EP0499755A1 (fr) * 1991-02-18 1992-08-26 MIDY S.p.A. Nouvelles phényléthanolaminotétralines, procédé pour leur préparation, intermédiaires dans ce procédé et compositions pharmaceutiques les contenant
GB9107827D0 (en) * 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
GB9207964D0 (en) * 1992-04-10 1992-05-27 Ici Plc Chemical compounds
GB9209076D0 (en) * 1992-04-27 1992-06-10 Ici Plc Chemical compounds
GB9215844D0 (en) * 1992-07-25 1992-09-09 Smithkline Beecham Plc Novel compounds
WO1994003425A2 (en) * 1992-07-31 1994-02-17 Syntex (U.S.A.) Inc. Carbostyril derivatives for the treatment of arrhythmia
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5321036A (en) * 1993-02-10 1994-06-14 Bristol-Myers Squibb Company Thiazole and oxazole-based β3 adrenergic receptor agonists
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
EP0627407A1 (fr) * 1993-05-28 1994-12-07 MIDY S.p.A. Acide (7S)-7-[(2R)-2(3-chlorophényl)-2-hydroxyéthylamino]-5,6,7,8-tétrahydronaphtalèn-2-yloxy acétique, ses sels pharmaceutiquement acceptables, à action agoniste bêta-3 adrénergique et compositions pharmaceutiques le contenant
AU675536B2 (en) * 1993-06-14 1997-02-06 Pfizer Inc. Secondary amines as antidiabetic and antiobesity agents
GB9313574D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments
EP0711284A1 (en) * 1993-07-31 1996-05-15 Smithkline Beecham Plc 2-benzoheterocyclyloxy or thiopropanolamine derivatives with adreno receptor agonist activity
IL110857A0 (en) * 1993-09-09 1994-11-28 Lilly Co Eli Cessation of tobacco use
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5541197A (en) * 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
CA2196193A1 (en) * 1994-07-29 1996-02-15 Lee James Beeley Aryloxy and arylthiopropanolamine derivatives useful as beta 3-adrenoreceptor agonists and antagonists of the beta 1 and beta 2-adrenoreceptors and pharmaceutical composition thereof
US5726165A (en) * 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
DE69711519T2 (de) * 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazolanaloge als selektive beta3-adrenergische Agonisten
WO2004036435A1 (ja) 2002-10-15 2004-04-29 Matsushita Electric Industrial Co., Ltd. デジタルアイテムの管理情報の管理システム
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
US7858121B2 (en) 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl

Also Published As

Publication number Publication date
MY132626A (en) 2007-10-31
ES2171839T3 (es) 2002-09-16
ATE215369T1 (de) 2002-04-15
US20050043337A1 (en) 2005-02-24
EP0827746A1 (en) 1998-03-11
AR009518A1 (es) 2000-04-26
US7041684B2 (en) 2006-05-09
AU4094197A (en) 1998-03-26
DE69711519D1 (de) 2002-05-08
US6413991B1 (en) 2002-07-02
EP0827746B1 (en) 2002-04-03
PE109398A1 (es) 1999-01-15
US6140352A (en) 2000-10-31
DE69711519T2 (de) 2002-10-31
WO1998009625A1 (en) 1998-03-12
US20020165234A1 (en) 2002-11-07
AR009519A1 (es) 2000-04-26
JP2002513387A (ja) 2002-05-08
JP4212117B2 (ja) 2009-01-21
ID17182A (id) 1997-12-04
US6686372B2 (en) 2004-02-03

Similar Documents

Publication Publication Date Title
CO4910132A1 (es) Agonistas adrenergicos selectivos de beta 3
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
ES2120535T3 (es) Agentes reticulantes con trifuncionalidad de carbamato.
AR010001A1 (es) Composiciones detergentes
CR6557A (es) Amidas heterociclicas aromaticas fungicidas y sus omposiciones, metodos preparacion y uso
AR240794A2 (es) Derivados de 2-(2'-nitrobenzoil)-1,3-ciclohexanodiona composicion herbicida que los comprende y procedimiento para prepararlos.
ES2135058T3 (es) Fosfito monodentado y composicion de catalizador a base de niquel para la hidrocianacion de monoolefinas.
TR199902552T2 (xx) Fungisidal triflorometilalkilamino-triazolopirimidinler.
ES2100187T3 (es) Derivados de carboestirilos y composiciones farmaceuticas que los contienen.
GT199900056A (es) Nuevas dihidropirimidinas
AR010331A1 (es) Compuestos derivados de 6-fenilpiridil-2-amina utiles como inhibidores nos, composiciones farmaceuticas que comprenden dichos compuestos, y metodosde tratamiento utilizando dichos compuestos.
AR042149A1 (es) Uso de aminas y/o aductos de mannich en composiciones de combustibles y lubricantes para motores otto de inyeccion directa
ES2009785B3 (es) Procedimiento para preparar derivados de tioxantona.
ES2081635T3 (es) 5,6-dihidroxiindolinas como aditivos para recetas de tinte para el cabello.
BR0004535A (pt) Compostos, e, uso dos mesmos.
ES2108595B1 (es) Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion.
FI852003A0 (fi) --laktamantibiotika, foerfarande foer deras framstaellning och deras anvaendning som laekemedel eller tillvaextbefraemjare vid boskapsuppfoedning eller som antioxidanter.
AR248283A1 (es) Procedimiento para preparar nuevos derivados de 2'-halometiliden, 2'-etiniliden y 2'-etiniladenosina, inhibidores de la transmetilacion dependiente de adomet.
ES2196069T3 (es) Derivados morfinoides condensados con heterociclos.
ES2041902T3 (es) Tinte para el cabello.
AR012553A1 (es) Una composicion que posee propiedades antivirales, en base a 7h-benz (de) antracenos y las composiciones farmaceuticas que los contienen conjuntamentecon derivados de la benzantrona
PH22537A (en) 3-aminocarbonylmethoxy-5-phenylpyrazole compounds and anti-arrythmic compositions containing them
PE86698A1 (es) Derivados de indolina
ES2036583T3 (es) Iminooxazolidinas, procedimiento de preparacion y metodo de uso.
MX9204194A (es) Los compuestos de 1,2,4-oxadiazolil-fenoxialquilisoxazolas y su uso como agentes antivirales